1. Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement.
- Author
-
García-Maturano JS, Torres-Ordaz DE, Mosqueda-Gutiérrez M, Gómez-Ruiz C, Vázquez-Mellado A, Tafoya-Amado A, Peláez-Ballestas I, Burgos-Vargas R, and Vázquez-Mellado J
- Subjects
- Allopurinol therapeutic use, Gout Suppressants therapeutic use, Humans, Male, Middle Aged, Pandemics, Prospective Studies, Quality of Life, SARS-CoV-2, Uric Acid, COVID-19, Gout drug therapy, Gout epidemiology
- Abstract
Introduction: Gout is the most common inflammatory arthritis, but was not considered in most COVID-19 and rheumatic diseases reports. Our aim was to describe changes in clinical data, treatment, function and quality of life for gout patients during COVID-19 pandemic., Methods: Prospective, descriptive and analytical study of 101 consecutive gout (ACR/EULAR 2015) patients from our clinic evaluated during pandemic by phone call (n=52) or phone call + face-to-face (n=68) that accepted to participate. Variables are demographics, clinical and treatment data, HAQ, EQ5D questionnaires and COVID-19-related data. Patients were divided in two groups: flare (n=36) or intercritical gout (n=65) also; available pre-pandemic data was obtained from 71 patients. Statistical analyses are X
2 , paired t-test and Wilcoxon test., Results: Included gout patients were males (95.8%), mean (SD) age 54.7 (10.7) years and disease duration 16.4 (9.8) years; 90% received allopurinol, 50% colchicine as prophylaxis and 25% suspended ≥ 1 medication. Comparison of pre-pandemic vs pandemic data showed > flares (4.4% vs 36%, p=0.01), more flares in the last 6 months: 0.31 (0.75) vs 1.71 (3.1), (p=0.004 and > urate levels: 5.6 (1.7)vs 6.7 (2.2) mg/dL, p=0.016. Unexpectedly, function and quality-of-life scores improved: HAQ score 0.65 (2.16) vs 0.12 (0.17), p= 0.001. Seven patients were COVID-19-confirmed cases; they had significantly more flares, higher urate levels and lower allopurinol doses and two died., Conclusions: In gout patients, flares were 9 times more frequent during pandemic also, they had increased urate levels but led to an unexpected improvement in HAQ and functionality scores. Resilience and lifestyle changes in gout during COVID-19 pandemic require further studies. Key Points • COVID-19 pandemic is associated with 4 times more flares in gout patients. • Increased flares were also seen in previously well-controlled gout patients. • Increased serum urate levels were also found in gout patients during pandemic. • In our gout clinic, 8/101 patients were diagnosed as COVID-19+, and two of them died., (© 2021. International League of Associations for Rheumatology (ILAR).)- Published
- 2022
- Full Text
- View/download PDF